Where are risk evaluation and mitigation strategies headed?

Johnson, Philip E.
September 2010
American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1511
Academic Journal
The article presents the author's views on the risk evaluation and mitigation strategies (REMSs) adopted by the U.S. Food and Drug Administration (FDA) to manage drug safety. He opines that proper implementation of REMSs can facilitate integration of all drug providers, patient information and treatment strategies into one process focusing on the overall patient care. According to him, the drug safety considerations should include decision algorithms to manage patients as per their unique needs.


Related Articles

  • Reformers seek greater transparency in drug prices, marketing, and research. Wechsler, Jill // Formulary;Mar2009, Vol. 44 Issue 3, p86 

    The article focuses on the prominent theme in health-reform. The U.S. Food and Drug Administration (FDA) had developed an online system for posting quarterly lists of drugs with potential signals of serious risks. Furthermore, FDA will issue Early Communication notices and had launched the drug...

  • Sentinel Initiative: Postmarket risk identification and analysis. Marchand, Heidi C. // Pharmacy Today;May2009, Vol. 15 Issue 5, p21 

    The article offers information on the Sentinel Initiative by the U.S. Food and Drug Administration (FDA) that would gather postmarket health care data across the country. It states that the initiative allows the agency to gather information about the safety and performance of regulated...

  • Mitigating the Safety Risks of Drugs With a Focus on Opioids: Are Risk Evaluation and Mitigation Strategies the Answer? Brooks, Marta J. // Mayo Clinic Proceedings;Dec2014, Vol. 89 Issue 12, p1673 

    Approximately 40% of all newly approved drugs are subject to safety restrictions inclusive of Risk Evaluation and Mitigation Strategies (REMS), which were created with the US Food and Drug Administration Amendments Act of 2007. This law expanded Food and Drug Administration (FDA) authority to...

  • Institute of Medicine Report Slams FDA.  // Quality Progress;Nov2006, Vol. 39 Issue 11, p16 

    The article reports on an independent federal report from the United States Institute of Medicine. The report echoes the harshest critics of the U.S. Food and Drug Administration's drug safety regimen. According to the report, the drug safety system of the country is feeble in its drug approval...

  • FDA outlines four areas for improving drug safety. Dickinson, James G. // Medical Marketing & Media;Aug2005, Vol. 40 Issue 8, p14 

    Discusses issues that should be addressed by the U.S. Food and Drug Administration (FDA) to improve drug safety in the country. Better surveillance systems; Access to additional data sources; Improved healthcare system quality; Medication-use processes; Mechanistic and personalized approaches to...

  • FDA goes after illegal Cipro Web sites. Dickinson, James G. // Medical Marketing & Media;Dec2001, Vol. 36 Issue 12, p22 

    Reports on the issuance of warning letters to foreign Web site operators selling illegal generic ciprofloxacin in the U.S. Protection to the public from harmful drugs; Inability of the Food and Drugs Administration to determine the specification of the drugs marketed by the Web sites.

  • Drug Safety Concerns Shape Manufacturing Policy. Wechsler, Jill // Pharmaceutical Technology Europe;Mar2002, Vol. 14 Issue 3, p13 

    Reports on the move of the U.S. Food and Drug Administration to improve processes for evaluating the risk factors in new drug candidates and for tracking and evaluating adverse events once a product is on the market. Effect of the campaign of the agency on the manufacturing process of the...

  • Drug Safety Alerts Almost Double. J. G. D. // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p32 

    The article focuses on a report released by the U.S. Food and Drug Administration (FDA) which reflects the increase of drug safety alerts in the country in 2011.

  • Drug safety provisions in US and Europe outshine Canada. Silversides, Ann // CMAJ: Canadian Medical Association Journal;1/12/2010 Supplement, Vol. 182, pE23 

    The article reports that new drug safety provisions are earning profits in the U.S. and Europe but the legislation to introduce new regulations in Canada are getting weakened. It is stated that U.S. Food and Drug Administration (FDA) is taking drug safety to a higher level and several new...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics